Devyser Diagnostics
120.00 SEK
+8.11 %
Less than 1K followers
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+8.11 %
+5.26 %
-19.14 %
+3.45 %
+1.27 %
-1.64 %
+69.64 %
-
+34.83 %
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Read moreMarket cap
2B SEK
Turnover
873.71K SEK
Revenue
216.9M
EBIT %
-26.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12.2
2026
Annual report '25
6.5
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada
Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
